

10501317

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	6	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	11	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	14	JUL 28	STN Viewer performance improved
NEWS	15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	16	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	18	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	21	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	23	SEP 29	IFICLS enhanced with new super search field
NEWS	24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields

Updated Search



10501317

=>


Uploading C:\Documents and Settings\brobinson1\My Documents\e-Red  
Folder\10524345\317.str

L1        STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1        STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:48:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        450 TO ITERATE

100.0% PROCESSED        450 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        7728 TO    10272

PROJECTED ANSWERS:        56 TO        504

L2        14 SEA SSS SAM L1

=> s l1 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 17:49:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -        8985 TO ITERATE

100.0% PROCESSED        8985 ITERATIONS

247 ANSWERS

Updated Search

10501317

SEARCH TIME: 00.00.01

L3 247 SEA \$\$\$ FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

181.58

181.79

FILE 'HCAPLUS' ENTERED AT 17:49:04 ON 10 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Oct 2008 VOL 149 ISS 16

FILE LAST UPDATED: 9 Oct 2008 (20081009/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 8 L3

=> s l4 and bromidge, s7/au

82 BROMIDGE, S7/AU

L5 2 L4 AND BROMIDGE, S7/AU

=> d l5, ibib abs hitstr, 1-2

L5 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2005:1084921 HCAPLUS


DOCUMENT NUMBER: 143:432011

TITLE: A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists

AUTHOR(S): Goodacre, Caroline J.; Bromidge, Steven M.; Clapham, David; King, Frank D.; Lovell, Peter J.; Allen, Mike; Campbell, Lorraine P.; Holland, Vicky; Riley, Graham J.; Starr, Kathryn R.; Trail, Brenda K.; Wood, Martyn D.

Updated Search

CORPORATE SOURCE: Psychiatry Centre of Excellence in Drug Discovery,  
GlaxoSmithkline Pharmaceuticals, Essex, CM19 5AW, UK  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005),  
15(22), 4989-4993  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 143:432011  
GI




AB Bisaryl cyclic ureas have been identified as high affinity 5-HT<sub>2C</sub> receptor antagonists with selectivity over 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub>. Compds. such as (I) and (II) have shown oral activity in a centrally mediated pharmacodynamic model of 5-HT<sub>2C</sub> function in rodents.

IT 561277-51-8P 561277-52-9P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT<sub>2C</sub> receptor antagonists)


RN 561277-51-8 HCAPLUS  
CN 2H-Imidazol-2-one, 1-(3-fluorophenyl)-1,3-dihydro-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)

10501317



RN 561277-52-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-(3,5-difluorophenyl)-1,3-dihydro-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



IT 561277-37-0P, 1-(3-Fluorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-38-1P  
 561277-39-2P 561277-40-5P 561277-41-6P  
 561277-42-7P, 1-[4-Methoxy-3-(2-(piperidinyl)ethoxy)phenyl]-3-phenylimidazolidin-2-one 561277-43-8P 561277-45-0P,  
 1-(3,4-Dichlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-46-1P 561277-47-2P  
 561277-50-7P, 1-(2,3-Dichlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-53-0P  
 868568-37-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT<sub>2C</sub> receptor antagonists)


RN 561277-37-0 HCAPLUS

CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(1-

Updated Search


10501317

piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 561277-38-1 HCAPLUS

CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 561277-39-2 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




Updated Search

10501317


RN 561277-40-5 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 561277-41-6 HCAPLUS

CN 2-Imidazolidinone, 1-(2-chlorophenyl)-3-[4-methoxy-3-[2-(1-piperidiny)ethoxy]phenyl]- (CA INDEX NAME)



RN 561277-42-7 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(1-piperidiny)ethoxy]phenyl]-3-phenyl- (CA INDEX NAME)




RN 561277-43-8 HCAPLUS

Updated Search




10501317

CN 2-Imidazolidinone, 1-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]-3-(3-fluorophenyl)- (CA INDEX NAME)



RN 561277-45-0 HCAPLUS


CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 561277-46-1 HCAPLUS


CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)

10501317




RN 561277-47-2 HCAPLUS

CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]- (CA INDEX NAME)



RN 561277-50-7 HCAPLUS

CN 2-Imidazolidinone, 1-(2,3-dichlorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 561277-53-0 HCAPLUS

Updated Search


10501317

CN 2,4-Imidazolidinedione, 3-(3-fluorophenyl)-1-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 868568-37-0 HCAPLUS

CN 2-Imidazolidinone, 1-(3,5-difluorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:551382 HCAPLUS

DOCUMENT NUMBER: 139:117423

TITLE: Preparation of cyclic urea derivatives with 5-HT2c receptor activity

INVENTOR(S): Bromidge, Steven Mark; Lovell, Peter John;

Goodacre, Caroline

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 36 pp.



CODEN: PIXXD2

Updated Search

10501317

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057220	A1	20030717	WO 2003-GB20	20030107
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003201636	A1	20030724	AU 2003-201636	20030107
EP 1465630	A1	20041013	EP 2003-700335	20030107
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 200524620	T	20050818	JP 2003-557578	20030107
US 20050154028	A1	20050714	US 2005-501317	20050222
PRIORITY APPLN. INFO.:			GB 2002-283	A 20020108
			WO 2003-GB20	W 20030107
OTHER SOURCE(S):	MARPAT 139:117423			
GI				



AB Title compds. I [p = 0-5; m = 1-3; Y = N, C; A = O, N, CONH, NHCO, etc.; R1 = halo, alkyl, alkoxy, alkylthio, etc.; R2 = H, halo, alkyl, alkoxy, haloalkyl, haloalkoxy; R3 = amino; X = CH2, CO] are prepared. For instance, 2-(3-fluorophenylamino)ethanol (preparation given) is reacted with MsCl/CH2Cl2 followed by 3-benzoyloxy-4-methoxyphenylamine to give the corresponding substituted diamine. This intermediate is treated with phosgene to give


1-(3-benzyloxy-4-methoxyphenyl)-3-(3-fluorophenyl)imidazolidin-2-one.  
Substitution of this using 1-(2-chloroethyl)piperidine•HCl  
(MeOCH<sub>2</sub>CH<sub>2</sub>OMe, K<sub>2</sub>CO<sub>3</sub>, reflux, 5 h) afforded II. I exhibit 5-HT<sub>2c</sub> receptor  
activity and are useful for the treatment of CNS disorders such as  
depression or anxiety.

IT 561277-37-0P, 1-(3-Fluorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-38-1P, 1-(3-Fluorophenyl)-3-[4-methoxy-3-(2-(morpholinyl)ethoxy)phenyl]imidazolidin-2-one 561277-39-2P, 1-(4-Methyl-3-trifluoromethylphenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-40-5P, 1-(4-Methyl-3-trifluoromethylphenyl)-3-[4-methoxy-3-(2-(morpholinyl)ethoxy)phenyl]imidazolidin-2-one 561277-41-6P, 1-(2-Chlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-42-7P, 1-[4-Methoxy-3-(2-(piperidinyl)ethoxy)phenyl]-3-phenylimidazolidin-2-one 561277-43-8P, 1-[3-(2-Dimethylaminoethoxy)-4-methoxyphenyl]-3-(3-fluorophenyl)imidazolidin-2-one 561277-44-9P 561277-45-0P, 1-(3,4-Dichlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-46-1P, 1-(3,4-Dichlorophenyl)-3-[4-methoxy-3-(2-(morpholinyl)ethoxy)phenyl]imidazolidin-2-one 561277-47-2P, 1-(3,4-Dichlorophenyl)-3-[3-(2-dimethylaminoethoxy)-4-methoxyphenyl]imidazolidin-2-one 561277-49-4P, 1-[4-Bromo-3-(2-(piperidinyl)ethoxy)phenyl]-3-(3,4-dichlorophenyl)imidazolidin-2-one 561277-50-7P, 1-(2,3-Dichlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-51-8P 561277-52-9P 561277-53-0P, 3-(3-Fluorophenyl)-1-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazol-2,4-dione  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic urea derivs. with 5-HT<sub>2c</sub> receptor activity)

RN 561277-37-0 HCAPLUS

CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 561277-38-1 HCAPLUS

CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(4-


10501317

morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 561277-39-2 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(1-piperidiny)ethoxy]phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 561277-40-5 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 561277-41-6 HCAPLUS

CN 2-Imidazolidinone, 1-(2-chlorophenyl)-3-[4-methoxy-3-[2-(1-piperidiny)ethoxy]phenyl]- (CA INDEX NAME)


Updated Search

10501317




RN 561277-42-7 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-3-phenyl- (CA INDEX NAME)



RN 561277-43-8 HCAPLUS

CN 2-Imidazolidinone, 1-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]-3-(3-fluorophenyl)- (CA INDEX NAME)




Updated Search

10501317

RN 561277-44-9 HCAPLUS


CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 561277-45-0 HCAPLUS

CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyloxy)phenyl]- (CA INDEX NAME)



RN 561277-46-1 HCAPLUS

CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[4-methoxy-3-[2-(4-morpholinylethoxy)phenyl]- (CA INDEX NAME)




RN 561277-47-2 HCAPLUS

CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]- (CA INDEX NAME)

Updated Search




10501317



RN 561277-49-4 HCAPLUS

CN 2-Imidazolidinone, 1-[4-bromo-3-[2-(1-piperidinyl)ethoxy]phenyl]-3-(3,4-dichlorophenyl)- (CA INDEX NAME)




RN 561277-50-7 HCAPLUS

CN 2-Imidazolidinone, 1-(2,3-dichlorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)


Updated Search

10501317



RN 561277-51-8 HCAPLUS


CN 2H-Imidazol-2-one, 1-(3-fluorophenyl)-1,3-dihydro-3-[4-methoxy-3-(2-(1-piperidinyl)ethoxy)phenyl]- (CA INDEX NAME)




RN 561277-52-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-(3,5-difluorophenyl)-1,3-dihydro-3-[4-methoxy-3-(2-(1-piperidinyl)ethoxy)phenyl]- (CA INDEX NAME)

10501317



RN 561277-53-0 HCAPLUS  
CN 2,4-Imidazolidinedione, 3-(3-fluorophenyl)-1-[4-methoxy-3-[(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:44:07 ON 10 OCT 2008)

FILE 'REGISTRY' ENTERED AT 17:44:16 ON 10 OCT 2008

L1 STRUCTURE UPLOADED

L2 14 S L1

L3 247 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:49:04 ON 10 OCT 2008

L4 8 S L3

L5 2 S L4 AND BROMIDGE, S?/AU

Updated Search

10501317

=> s 14 not 15  
L6 6 L4 NOT L5  
  
=> s 16 and lovell, p?/au  
188 LOVELL, P?/AU  
L7 0 L6 AND LOVELL, P?/AU  
  
=> s 16 and goodacre, c?/au  
20 GOODACRE, C?/AU  
L8 0 L6 AND GOODACRE, C?/AU  
  
=> d 16, ibib abs hitstr, 1-6

L6 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:652190 HCAPLUS

DOCUMENT NUMBER: 147:277517

TITLE: Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists  
AUTHOR(S): Balavoine, Fabrice; Malabre, Patrice; Alleaume, Thierry; Rey, Astrid; Cherfils, Valerie; Jeanneton, Olivier; Seigneurin-Venin, Sophie; Revah, Frederic

CORPORATE SOURCE: Villebon sur Yvette, 91951, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(13), 3754-3759

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:277517

AB We report here new chemical series acting as antagonists of melanin-concentrating

hormone receptor 1 (MCHR-1). Synthesis and structure-activity relationships are described leading to the identification of compds. with optimized in vitro pharmacol. and in vitro ADME profiles. In vivo activity has been demonstrated in animal models of food intake and depression.

IT 923030-45-9P 923030-48-2P 946125-64-0P

946125-66-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation of hydantoin-containing heterocyclic compds. using amidation

and

heterocyclization as key steps, and their antiobesity activity as melanin-concentrating hormone receptor antagonist and SAR)

RN 923030-45-9 HCAPLUS


CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 923030-48-2 HCAPLUS  
 CN 2,4-Imidazolidinedione, 3-[1,1'-biphenyl]-4-yl-1-[3-methoxy-4-{2-(1-pyrrolidinyl)ethoxy}phenyl]- (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 946125-64-0 HCAPLUS  
CN 2,4-Imidazolidinedione, 1-[1,1'-biphenyl]-4-yl-3-[3-methoxy-4-(2-(1-pyrrolidinyl)ethoxy)phenyl]- (CA INDEX NAME)

Updated Search

10501317

PAGE 1-A




PAGE 2-A



RN 946125-66-2 HCAPLUS  
CN 2,4-Imidazolidinedione, 3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-1-  
(4-phenoxypyphenyl)- (CA INDEX NAME)

Updated Search



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:117937 HCAPLUS  
 DOCUMENT NUMBER: 146:206302  
 TITLE: Preparation of hydantoin derivatives and their use as MCHR-1 antagonists  
 INVENTOR(S): Balavoine, Fabrice; Nicolaie, Eric; Sartori, Eric  
 PATENT ASSIGNEE(S): Cerep, Fr.  
 SOURCE: PCT Int. Appl., 92pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007012661	A1	20070201	WO 2006-EP64747	20060727



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

FR 2889189

A1

20070202

FR 2005-8064

20050728

PRIORITY APPLN. INFO.:


FR 2005-8064

A 20050728


OTHER SOURCE(S):

MARPAT 146:206302

GI



I




II

AB Title compds. I [Arl = (un)substituted aryl, heteroaryl, cycloalkyl, heterocyclyl; L1 = bond, alkylene, alkyleneoxy, alkoxyalkylene, alkylidene, alkylidenoxy; R1, R2 = H, alkyl; R1 or R2 can form with Ar2 or L and with the C and N atoms of the hydantoin ring to which they are attached a 5-7 membered heterocycle; when R1 or R2 binds to Ar2 or L, then R1 or R2 = alkylene; L = bond, alkylene, alkyleneoxy, alkylidene; Ar2 = (un)substituted aryl, heteroaryl, heterocyclyl; L2 = alkylene, alkyleneoxy, alkylidene, etc.; Q = NH2 and derivs.] were prepared as melanin-concentrating hormone receptor type 1 (MCHR-1) antagonists for treating and prevention of diseases associated with MCHR receptors such as obesity, anorexia, weight loss, depression and/or anxiety. Thus, O-alkylation of 2-methoxy-4-nitrophenol potassium salt with 1-(2-chloroethyl)pyrrolidine.HCl, reduction of the nitro intermediate, reaction of the amine with Et glyoxylate, and cyclization with 4-phenoxyphenyl isocyanate gave II. I displayed a good affinity for the MCHR-1 receptors (IC50 < 200 nM for II). The antagonistic activity of hydantoins I was demonstrated in a fluorescence assay following the intracellular calcium release induced by MCH (no data).

IT 923030-45-9P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-48-2P, 3-(Biphenyl-4-yl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-49-3P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(3-phenoxyphenyl)imidazolidine-2,4-dione 923030-50-6P, 3-(4-Butoxyphenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-51-7P, 3-(4-Benzylphenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-60-8P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-phenylimidazolidine-2,4-dione 923030-61-9P, 3-(4-Chlorophenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-62-0P, 3-(4-Methoxyphenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-63-1P, 3-(4-Bromophenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-64-2P, 3-(4-Fluorophenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-65-3P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(4-methylphenyl)imidazolidine-2,4-dione 923030-66-4P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 923030-67-5P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(4-trifluoromethylphenyl)imidazolidine-2,4-dione 923030-68-6P, 3-(4-Cyanophenyl)-1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-69-7P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-[4-(4-chlorophenoxy)phenyl]imidazolidine-2,4-dione 923030-70-0P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-5-methyl-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-76-6P, 1-[4-[2-(Cyclopentylamino)ethoxy]-3-methoxyphenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-80-2P, 1-[4-(2-Dimethylaminoethoxy)-3-methoxyphenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-81-3P, 1-[4-(2-Diethylaminoethoxy)-3-methoxyphenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-82-4P, 1-[3-Methoxy-4-[2-(morpholin-4-yl)ethoxy]phenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-83-5P, 1-[4-[2-(4-Acetylpiperazin-1-yl)ethoxy]-3-methoxyphenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-84-6P, 1-[3-Methoxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of hydantoins as MCHR-1 antagonists)  
 RN 923030-45-9 HCAPLUS  
 CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 923030-48-2 HCAPLUS  
CN 2,4-Imidazolidinedione, 3-[1,1'-biphenyl]-4-yl-1-[3-methoxy-4-{2-(1-pyrrolidinyl)ethoxy}phenyl]- (CA INDEX NAME)

Updated Search

10501317

PAGE 1-A




PAGE 2-A



RN 923030-49-3 HCAPLUS  
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-(3-phenoxyphenyl)- (CA INDEX NAME)


Updated Search



RN 923030-50-6 HCAPLUS  
 CN 2,4-Imidazolidinedione, 3-(4-butoxyphenyl)-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

10501317

PAGE 1-A




PAGE 2-A




RN 923030-51-7 HCAPLUS  
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)

Updated Search



RN 923030-60-8 HCAPLUS

CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-phenyl- (CA INDEX NAME)




RN 923030-61-9 HCAPLUS

CN 2,4-Imidazolidinedione, 3-(4-chlorophenyl)-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 923030-62-0 HCAPLUS  
CN 2,4-Imidazolidinedione, 3-(4-methoxyphenyl)-1-[3-methoxy-4-[2-(1-methylpyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Updated Search



10501317

PAGE 1-A



PAGE 2-A




RN 923030-63-1 HCAPLUS  
CN 2,4-Imidazolidinedione, 3-(4-bromophenyl)-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 923030-64-2 HCAPLUS  
CN 2,4-Imidazolidinedione, 3-(4-fluorophenyl)-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 923030-65-3 HCAPLUS  
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-(4-methylphenyl)- (CA INDEX NAME)

Updated Search

10501317

PAGE 1-A




PAGE 2-A




RN 923030-66-4 HCAPLUS  
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Updated Search




RN 923030-67-5 HCAPLUS  
 CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 923030-68-6 HCAPLUS  
CN Benzonitrile, 4-[3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,5-dioxo-1-imidazolidinyl]- (CA INDEX NAME)

10501317

PAGE 1-A





PAGE 2-A



RN 923030-69-7 HCAPLUS  
CN 2,4-Imidazolidinedione, 3-[4-(4-chlorophenoxy)phenyl]-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Updated Search




RN 923030-70-0 HCAPLUS

CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5-methyl-3-(4-phenoxyphenyl)- (CA INDEX NAME)



10501317

PAGE 1-A



PAGE 2-A




RN 923030-76-6 HCAPLUS  
CN 2,4-Imidazolidinedione, 1-[4-[2-(cyclopentylamino)ethoxy]-3-methoxyphenyl]-  
3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search

10501317

PAGE 1-A




PAGE 2-A



RN 923030-80-2 HCAPLUS  
CN 2,4-Imidazolidinedione, 1-[4-[2-(dimethylamino)ethoxy]-3-methoxyphenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)


Updated Search

10501317




RN 923030-81-3 HCAPLUS

CN 2,4-Imidazolidinedione, 1-[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 923030-82-4 HCAPLUS

CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)




Updated Search

10501317


RN 923030-83-5 HCAPLUS

CN 2,4-Imidazolidinedione, 1-[4-[2-(4-acetyl-1-piperazinyl)ethoxy]-3-methoxyphenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 923030-84-6 HCAPLUS

CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:740674 HCAPLUS

DOCUMENT NUMBER: 145:167252

TITLE: Preparation of ureido substituted benzoic acids, particularly (imidazolidin-1-yl)benzoic acids, as promoters of nonsense mutation suppression in messenger RNA (mRNA) and/or as modulators of translation termination for treatment of related diseases

INVENTOR(S): Wilde, Richard G.; Takasugi, James J.; Hwang, Seongwoo; Welch, Ellen M.; Chen, Guangming

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 70 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060167065	A1	20060727	US 2005-48656	20050121
US 7405233	B2	20080729		

Updated Search

WO 2004009558 A2 20040129 WO 2003-US23182 20030723  
 WO 2004009558 A3 20040415  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 PRIORITY APPLN. INFO.: US 2002-398333P P 20020724  
 WO 2003-US23182 A1 20030723  
 OTHER SOURCE(S): MARPAT 145:167252  
 GI



AB Title compds. I [X = CO, C(:S), S, SO, SO<sub>2</sub>; Y = (un)substituted cyclo/alkyl, hetero/aryl, heterocyclyl; R = H, (un)substituted cyclo/alkyl, hetero/aryl, etc.; Z = (CH<sub>2</sub>)<sub>n</sub>; n = 0-4; R<sub>1</sub>, R<sub>2</sub> = independently H, (un)substituted alk(en/yn)yl, alkylcarbonyl, etc.; or R<sub>1</sub>CNR<sub>2</sub>, R<sub>1</sub>NSNR<sub>2</sub> = (un)substituted 5-7 membered heterocyclyl, 5-7 membered heteroaryl; or R<sub>1</sub>-R<sub>2</sub> = COCH<sub>2</sub>, CH<sub>2</sub>CO, CH<sub>2</sub>CH<sub>2</sub>, CH:CH, etc.; R<sub>3</sub>-R<sub>6</sub> = independently H, OH, CN, halo, (un)substituted alk(en/yn)yl, aryl, alkoxy, etc.; and their pharmaceutically acceptable salts, hydrates, solvates, clathrates, and stereoisomers] were prepared as promoters of nonsense mutation suppression in mRNA (mRNA) and/or as modulators of translation termination. Thus, II was prepared, in 5 steps, by amination of bromoacetyl bromide with Me 3-aminobenzoate, acylation of 4-isopropylaniline with the acyl bromide, reduction of the amide, cyclization in 1,2-dichloroethane in the presence of CDI, and saponification. Selected I showed both very high potency and efficacy of protein synthesis in a cell-based luciferase assay (no data).


Thus, I are useful for treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.

IT 651749-02-9P, 3-[2-Oxo-3-[4-[2-oxo-2-(4-phenylpiperazin-1-yl)ethoxy]phenyl]imidazolidin-1-yl]benzoic acid 651749-18-7P, 3-[3-[4-[2-(Morpholin-4-yl)-2-oxoethoxy]phenyl]-2-oxoimidazolidin-1-yl]benzoic acid 651749-19-8P, 3-[3-[4-[2-(4-Methylpiperazin-1-yl)-2-oxoethoxy]phenyl]-2-oxoimidazolidin-1-yl]benzoic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of ureido substituted benzoic acids as promoters of nonsense mutation suppression in mRNA and/or as modulators of translation termination)


RN 651749-02-9 HCAPLUS

CN Benzoic acid, 3-[2-oxo-3-[4-[2-oxo-2-(4-phenyl-1-piperazinyl)ethoxy]phenyl]-1-imidazolidinyl]- (CA INDEX NAME)




RN 651749-18-7 HCAPLUS

CN Benzoic acid, 3-[3-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-2-oxo-1-imidazolidinyl]- (CA INDEX NAME)



RN 651749-19-8 HCAPLUS

CN Benzoic acid, 3-[3-[4-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]phenyl]-2-oxo-1-imidazolidinyl]- (CA INDEX NAME)



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10501317

L6 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1016895 HCAPLUS

DOCUMENT NUMBER: 143:415586

TITLE: G-Protein-Coupled Receptor Affinity Prediction Based on the Use of a Profiling Dataset: QSAR Design, Synthesis, and Experimental Validation

AUTHOR(S): Rolland, Catherine; Gozalbes, Rafael; Nicolaie, Eric; Paugam, Marie-France; Coussy, Laurent; Barbosa, Frederique; Horvath, Dragos; Revah, Frederic

CORPORATE SOURCE: Cerep, Rueil-Malmaison, 92500, Fr.  
SOURCE: Journal of Medicinal Chemistry (2005), 48(21), 6563-6574

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A QSAR model accounting for "average" G-protein-coupled receptor (GPCR) binding was built from a large set of exptl. standardized binding data (1939 compds. systematically tested over 40 different GPCRs) and applied to the design of a library of "GPCR-predicted" compds. Three hundred and sixty of these compds. were randomly selected and tested in 21 GPCR binding assays. Positives were defined by their ability to inhibit by more than 70% the binding of reference compds. at 10  $\mu$ M. A 5.5-fold enrichment in positives was observed when comparing the "GPCR-predicted" compds. with 600 randomly selected compds. predicted as "non-GPCR" from a general collection. The model was efficient in predicting strongest binders, since enrichment was greater for higher cutoffs. Significant enrichment was also observed for peptidic GPCRs and receptors not included to develop the QSAR model, suggesting the usefulness of the model to design ligands binding with newly identified GPCRs, including orphan ones.


IT 654010-68-1

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

RN 654010-68-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:101141 HCAPLUS

DOCUMENT NUMBER: 140:163866

TITLE: Preparation of 1,3-dihydro-1,3-diphenyl-2H-imidazol-2-ones and related compounds as MCH receptor modulators for the treatment of obesity

INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas; Hessler, Gerhard; Rosse, Gerard; Walser, Armin

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011438	A1	20040205	WO 2003-EP7891	20030718
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10233817	A1	20040212	DE 2002-10233817	20020725
WO 2004012648	A2	20040212	WO 2003-EP7639	20030715
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			




GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
 TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2003257465 A1 20040223 AU 2003-257465 20030715  
 CA 2493924 A1 20040205 CA 2003-2493924 20030718  
 AU 2003251001 A1 20040216 AU 2003-251001 20030718  
 BR 2003012916 A 20050614 BR 2003-12916 20030718  
 EP 1551810 A1 20050713 EP 2003-771060 20030718  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2006501202 T 20060112 JP 2004-523753 20030718  
 US 20040132752 A1 20040708 US 2003-626314 20030724  
 US 7141561 B2 20061128  
 MX 2005PA01048 A 20050408 MX 2005-PA1048 20050125  
 PRIORITY APPLN. INFO.: DE 2002-10233817 A 20020725  
 US 2002-428877P P 20021125  
 WO 2003-EP7639 W 20030715  
 WO 2003-EP7891 W 20030718  
 OTHER SOURCE(S): MARPAT 140:163866  
 GI



I




II



III


- AB Title compds. I [R = alkyl, alkylaryl, cycloalkyl, etc.; A = (C(R42)(R43))m; m = 0-5; R42, R43 = H, alkyl, aryl; B = a bond or a link, i.e. S, SO, SO2, etc.; W = (CH2)n, CH=CH, CH=N, etc.; n = 2-5; R9, R10 = H, alkyl, alkoxyalkyl, etc.; R1, R2, R3, R4 = H, halo, OH, etc.; R5, R6, R7, R8 = H, halo, OH, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, TFA catalyzed cyclization of di-Me acetal II, e.g., prepared from 4-phenoxyaniline in 2-steps, afforded diarylcyclic urea III. In milk consumption studies with female NMRI mice, cyclic urea III exhibited very good anorectic effects, i.e., 58% decrease in milk consumption vs control. Compds. I are claimed useful as antiobesity and antidiabetic agents.
- IT 654022-95-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of diarylcyclic ureas as MCH receptor modulators for the treatment of obesity)
- RN 654022-95-4 HCAPLUS
- CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-hydroxyphenyl)- (CA INDEX NAME)



Me<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-O

- IT 654019-23-5P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (target compound; preparation of diarylcyclic ureas as MCH receptor modulators for the treatment of obesity)
- RN 654019-23-5 HCAPLUS
- CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(methylamino)ethoxy]phenyl]- (CA INDEX NAME)

10501317



IT 654010-68-1P 654010-85-2P 654010-92-1P  
654010-99-8P 654011-07-1P 654011-22-0P  
654011-41-3P 654011-47-9P 654011-54-8P  
654011-60-6P 654011-65-1P 654011-71-9P  
654011-76-4P 654011-82-2P 654011-88-8P  
654011-93-5P 654011-99-1P 654012-05-2P  
654012-10-9P 654012-16-5P 654012-21-2P  
654012-27-8P 654012-33-6P 654012-37-0P  
654012-43-8P 654012-48-3P 654012-58-5P  
654012-63-2P 654012-69-8P 654012-75-6P  
654012-80-3P 654012-86-9P 654012-92-7P  
654012-97-2P 654013-02-2P 654013-06-6P  
654013-10-2P 654013-15-7P 654013-18-0P  
654013-21-5P 654013-26-0P 654013-30-6P  
654013-35-1P 654013-41-9P 654013-47-5P  
654013-51-1P 654013-57-7P 654013-60-2P  
654013-63-5P 654013-67-9P 654013-72-6P  
654013-76-0P 654013-80-6P 654013-84-0P  
654013-87-3P 654013-91-9P 654013-94-2P  
654013-97-5P 654014-00-3P 654014-02-5P  
654014-05-8P 654014-09-2P 654014-11-6P  
654014-13-8P 654014-15-0P 654014-19-4P  
654014-24-1P 654014-29-6P 654014-34-3P  
654014-38-7P 654014-43-4P 654014-49-0P  
654014-53-6P 654014-59-2P 654014-64-9P  
654014-68-3P 654014-73-0P 654014-78-5P  
654014-82-1P 654014-88-7P 654014-93-4P  
654014-97-8P 654015-02-8P 654015-08-4P  
654015-13-1P 654015-19-7P 654015-24-4P  
654015-32-4P 654015-37-9P 654015-42-6P  
654015-47-1P 654015-51-7P 654015-57-3P  
654015-62-0P 654015-66-4P 654015-71-1P  
654015-76-6P 654015-81-3P 654015-86-8P  
654015-91-5P 654015-96-0P 654016-02-1P

Updated Search

654016-07-6P 654016-10-1P 654016-15-6P  
 654016-21-4P 654016-25-8P 654016-29-2P  
 654016-34-9P 654016-39-4P 654016-45-2P  
 654016-49-6P 654016-53-2P 654016-58-7P  
 654016-63-4P 654016-68-9P 654016-73-6P  
 654016-79-2P 654016-82-7P 654016-86-1P  
 654016-90-7P 654016-94-1P 654017-02-4P  
 654017-07-9P 654017-11-5P 654017-15-9P  
 654017-20-6P 654017-25-1P 654017-30-8P  
 654017-35-3P 654017-40-0P 654017-45-5P  
 654017-50-2P 654017-55-7P 654017-60-4P  
 654017-64-8P 654017-68-2P 654017-73-9P  
 654017-78-4P 654017-83-1P 654017-87-5P  
 654017-92-2P 654017-97-7P 654018-02-7P  
 654018-07-2P 654018-12-9P 654018-17-4P  
 654018-21-0P 654018-26-5P 654018-31-2P  
 654018-36-7P 654018-41-4P 654018-46-9P  
 654018-51-6P 654018-56-1P 654019-01-9P  
 654019-07-5P 654019-28-0P 654019-35-9P  
 654019-41-7P 654019-47-3P 654019-52-0P  
 654019-57-5P 654019-63-3P 654019-69-9P  
 654019-73-5P 654019-79-1P 654019-84-8P  
 654019-89-3P 654019-94-0P 654019-99-5P  
 654020-05-0P 654020-10-7P 654020-15-2P  
 654020-20-9P 654020-25-4P 654020-29-8P  
 654020-35-6P 654020-41-4P 654020-46-9P  
 654020-51-6P 654020-56-1P 654020-60-7P  
 654020-66-3P 654020-71-0P 654020-75-4P  
 654020-80-1P 654020-86-7P 654020-92-5P  
 654020-99-2P 654021-04-2P 654021-10-0P  
 654021-16-6P 654021-22-4P 654021-27-9P  
 654021-32-6P 654021-37-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(target compound; preparation of diarylcyclic ureas as MCH receptor  
 modulators  
 for the treatment of obesity)

RN 654010-68-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-  
 phenoxyphenyl)- (CA INDEX NAME)

10501317




RN 654010-85-2 HCAPLUS

CN Formic acid, compd. with 1,3-dihydro-1-(4-phenoxymethyl)-3-[3-(phenylmethyl)-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2H-imidazol-2-one (1:1)  
(CA INDEX NAME)

CM 1

CRN 654010-84-1

CMF C34 H33 N3 O3



CM 2

CRN 64-18-6

CMF C H2 O2


O=CH-OH

RN 654010-92-1 HCAPLUS

CN 2H-imidazol-2-one, 1,3-dihydro-1-(4-phenoxymethyl)-3-[4-[2-[(2-phenylethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)

Updated Search

10501317




RN 654010-99-8 HCAPLUS

CN Formic acid, compd. with 1,3-dihydro-1-[4-[2-(methilamino)ethoxy]phenyl]-3-(4-phenoxyphenyl)-2H-imidazol-2-one (1:1) (CA INDEX NAME)

CM 1

CRN 654010-98-7

CMF C24 H23 N3 O3



CM 2

CRN 64-18-6

CMF C H2 O2



Updated Search

10501317


RN 654011-07-1 HCAPLUS

CN Formic acid, compd. with 1-[4-(2-aminoethoxy)phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)-2H-imidazol-2-one (1:1) (CA INDEX NAME)

CM 1

CRN 654011-06-0

CMF C23 H21 N3 O3



CM 2

CRN 64-18-6

CMF C H2 O2



RN 654011-22-0 HCAPLUS

CN 2H-imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[(1R,2S)-2-(dimethylamino)-1-phenylpropoxy]phenyl]-1,3-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 654011-21-9

CMF C31 H35 N3 O3

Absolute stereochemistry.

Updated Search

10501317



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 654011-41-3 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search




10501317



RN 654011-47-9 HCAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(1R,5S)-1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl]ethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.





RN 654011-54-8 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(4-thiomorpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 654011-60-6 HCAPLUS



CN 3-Piperidinecarboxamide, 1-[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]-N,N-diethyl- (CA INDEX NAME)



RN 654011-65-1 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654011-71-9 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-[methyl[2-(2-pyridinyl)ethyl]amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654011-76-4 HCAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(4-phenylbutyl)amino]ethoxy]phenyl]- (CA INDEX NAME)


10501317



RN 654011-82-2 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(cyclopentyl-2-propen-1-ylamino)ethoxy]phenyl]-  
 1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)


PAGE 1-A







RN 654011-88-8 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(2-phenoxyethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



PhO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>2</sub>-O-

RN 654011-93-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[(2-(1-cyclohexen-1-yl)ethyl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654011-99-1 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[[[(1-hydroxycyclohexyl)methyl]amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)]- (CA INDEX NAME)




RN 654012-05-2 HCAPLUS  
 CN 2H-Azepin-2-one, 3-([2-[4-(2-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl)amino]hexahydro-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.




10501317



RN 654012-10-9 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(4-phenoxyphenyl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654012-16-5 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654012-21-2 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-[(5-hydroxypentyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)


10501317




RN 654012-27-8 HCAPLUS



CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(tetrahydro-2-furanyl)methylamino]ethoxy]phenyl]- (CA INDEX NAME)

PAGE 1-A






RN 654012-33-6 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(4-hydroxy-1-piperidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654012-37-0 HCAPLUS

10501317


CN 2H-Imidazol-2-one, 1-[4-[2-(3,4-dihydro-2(1H)-isoquinoliny1)ethoxy]phenyl]-  
1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654012-43-8 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(4-methyl-1-piperidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



10501317


RN 654012-48-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[(diphenylmethyl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654012-58-5 HCAPLUS



CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(phenylmethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)





RN 654012-63-2 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(2-thienylmethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)

Updated Search



RN 654012-69-8 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[4-(phenylmethyl)-1-piperidinyl]ethoxy]phenyl]- (CA INDEX NAME)




RN 654012-75-6 HCAPLUS

CN 2H-imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(3-thiazolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 654012-80-3 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(2-phenylethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search




10501317



RN 654012-86-9 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(cyclopropylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)


PAGE 1-A





RN 654012-92-7 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(cyclohexylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654012-97-2 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-[(1,1-dimethylethyl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)

10501317




RN 654013-02-2 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-{2-[(4-pyridinyl)ethyl]amino}ethoxy]phenyl- (CA INDEX NAME)


PAGE 1-A




Updated Search



RN 654013-06-6 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(1-methylethyl)amino]ethoxy]phenyl]  
 ]-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654013-10-2 HCAPLUS  
 CN Acetamide, N-[1-[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]-3-pyrrolidinyl]- (CA INDEX NAME)



RN 654013-15-7 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-([2-(4-hydroxy-4-phenyl-1-piperidinyl)ethoxy]phenyl)-3-(4-phenoxyphenyl)- (CA INDEX NAME)

10501317

PAGE 1-A




PAGE 2-A



RN 654013-18-0 HCAPLUS


CN 2H-imidazol-2-one, 1,3-dihydro-1-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search



RN 654013-21-5 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]- (CA INDEX NAME)




RN 654013-26-0 HCAPLUS

CN L-Proline, 1-[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10501317



RN 654013-30-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-{2-[(2,3-dihydro-1H-inden-2-yl)amino]ethoxy}phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654013-35-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-{2-(2-ethyl-1-piperidinyl)ethoxy}phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)

10501317

PAGE 1-A




PAGE 2-A




RN 654013-41-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[(cyclopropylmethyl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search




RN 654013-47-5 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-[(2,3-dihydro-1H-inden-1-yl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654013-51-1 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(4-phenyl-1-piperazinyl)ethoxy]phenyl]- (CA INDEX NAME)

10501317




RN 654013-57-7 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-{2-[(2-phenylethyl)-1-piperazinyl]ethoxy}phenyl]- (CA INDEX NAME)





RN 654013-60-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-{2-(1H-benzimidazol-1-yl)ethoxy}phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654013-63-5 HCAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-{2-[(2-(3-methoxyphenyl)ethyl)amino]ethoxy}phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654013-67-9 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654013-72-6 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(4-ethyl-1-piperazinyl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654013-76-0 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654013-80-6 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(3-hydroxy-1-pyrrolidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654013-84-0 HCAPLUS

CN 2H-imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-{2-[(1R,2S)-2-phenylcyclopropyl]amino}ethoxy]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




10501317



RN 654013-87-3 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 654013-91-9 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 654013-94-2 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[[2-(1H-indol-3-yl)ethyl]methylamino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search


10501317




RN 654013-97-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-([2-(2-chlorophenyl)ethyl]amino)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




Updated Search

10501317


RN 654014-00-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[(5-chloro-2-thienyl)methyl]amino]ethoxy]phenyl  
1]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 654014-02-5 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(1R,2R)-2-(phenylmethoxy)cyclopentyl]amino]ethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10501317



RN 654014-05-8 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[[[(2S)-1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl]amino]ethoxy]phenyl]- (CA INDEX NAME)



Absolute stereochemistry.



RN 654014-09-2 HCAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-1-[2-[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search





RN 654014-11-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-{2-(5-bromo-2,3-dihydro-1H-indol-1-yl)ethoxy}phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)





RN 654014-13-8 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-{2-(5-ethyl-2-methyl-1-piperidinyl)ethoxy}phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654014-15-0 HCAPLUS  
 CN 2H-imidazol-2-one, 1-[4-(2-(2,5-dimethyl-1-pyrrolidinyl)ethoxy)phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654014-19-4 HCAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(methylpropylamino)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

10501317




RN 654014-24-1 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(2-[(1,3-dioxolan-2-ylmethyl)methylamino]ethoxy)phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)


PAGE 1-A








RN 654014-29-6 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(2-methyl-1-pyrrolidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654014-34-3 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(1-methylethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)


10501317



RN 654014-38-7 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 654014-43-4 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

10501317




RN 654014-49-0 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(2-methoxyethyl)methylamino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654014-53-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(7-azabicyclo[2.2.1]hept-7-yl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654014-59-2 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(1-(phenylmethyl)-3-pyrrolidinyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 654014-64-9 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(tetrahydro-1,1-dioxido-3-


10501317

thienyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 654014-68-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[(diphenylmethyl)methylamino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 654014-73-0 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[[ (4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]methylamino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

10501317



RN 654014-78-5 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-{2-[3-(dimethylamino)-1-pyrrolidinyl]ethoxy}phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




Updated Search





RN 654014-82-1 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(2-phenyl-1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 654014-88-7 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(2-phenylmethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (CA INDEX NAME)




RN 654014-93-4 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(2-phenylethyl)-1-pyrrolidinyl]ethoxy]phenyl- (CA INDEX NAME)




10501317

PAGE 1-A




PAGE 2-A




RN 654014-97-8 HCAPLUS  
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[2-(1-methylethyl)-1-pyrrolidinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search




RN 654015-02-8 HCAPLUS  
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(3-phenyl-1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 654015-08-4 HCAPLUS  
 CN 2H-imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-{2-[(3-phenylmethyl)-1-pyrrolidinyl]ethoxy}phenyl]- (CA INDEX NAME)

10501317

PAGE 1-A





PAGE 2-A




RN 654015-13-1 HCAPLUS  
CN 2H-imidazol-2-one, 1,3-dihydro-1-([2-[3-(methanesulfonyl)-1-pyrrolidinyl]ethoxy]phenyl)-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search




RN 654015-19-7 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(1-methylpropoxy)phenyl]- (CA INDEX NAME)

10501317



RN 654015-24-4 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(1-phenylethoxy)phenyl]- (CA INDEX NAME)



RN 654015-32-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(1-methylbutoxy)phenyl]- (CA INDEX NAME)


10501317



RN 654015-37-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-[(2-methylphenyl)methoxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



Updated Search





RN 654015-42-6 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-  
 [(3-methylphenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 654015-47-1 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-  
 [(4-methylphenyl)methoxy]phenyl]- (CA INDEX NAME)






RN 654015-51-7 HCAPLUS  
 CN 2H-imidazol-2-one, 1-[4-{2-(dimethylamino)ethoxy}phenyl]-3-[4-(2,2-dimethylpropoxy)phenyl]-1,3-dihydro- (CA INDEX NAME)

10501317



RN 654015-57-3 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-methylpropoxy)phenyl]- (CA INDEX NAME)




RN 654015-62-0 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(2-ethylbutoxy)phenyl]-1,3-dihydro- (CA INDEX NAME)

10501317




RN 654015-66-4 HCAPLUS  
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-(4-ethoxyphenyl)-1,3-dihydro- (CA INDEX NAME)



RN 654015-71-1 HCAPLUS  
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-methoxyethoxy)phenyl]- (CA INDEX NAME)


Updated Search

10501317



RN 654015-76-6 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-propyn-1-yloxy)phenyl]- (CA INDEX NAME)



RN 654015-81-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-propen-1-yloxy)phenyl]- (CA INDEX NAME)


10501317



RN 654015-86-8 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[(2E)-2-buten-1-yloxy]phenyl]-3-[4-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 654015-91-5 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-propoxyphenyl)- (CA INDEX NAME)

Updated Search

10501317




RN 654015-96-0 HCAPLUS  
CN 2H-Imidazol-2-one, 1-[4-(3-buten-1-yloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)




RN 654016-02-1 HCAPLUS  
CN 2H-Imidazol-2-one, 1-(4-butoxyphenyl)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

10501317




RN 654016-07-6 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(hexyloxy)phenyl]-1,3-dihydro- (CA INDEX NAME)




RN 654016-10-1 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopropylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

10501317



RN 654016-15-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)



RN 654016-21-4 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclohexylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Updated Search



10501317

PAGE 1-A




PAGE 2-A



RN 654016-25-8 HCAPLUS  
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(1,3-dioxolan-2-ylmethoxy)phenyl]-1,3-dihydro- (CA INDEX NAME)


Updated Search

10501317



RN 654016-29-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclohexyloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)




RN 654016-34-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cycloheptyloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Updated Search


10501317



RN 654016-39-4 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]- (CA INDEX NAME)

PAGE 1-A






RN 654016-45-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-  
[(4-methylcyclohexyl)oxy]phenyl]- (CA INDEX NAME)

RN 654016-49-6 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-  
[(tetrahydro-2-furanyl)methoxy]phenyl]- (CA INDEX NAME)

10501317



RN 654016-53-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(1-ethylbutoxy)phenyl]-1,3-dihydro- (CA INDEX NAME)




RN 654016-58-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(4-fluorobutoxy)phenyl]-1,3-dihydro- (CA INDEX NAME)


Updated Search

10501317



RN 654016-63-4 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclobutylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)



RN 654016-68-9 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(3,3-dimethylbutoxy)phenyl]-1,3-dihydro- (CA INDEX NAME)

10501317




RN 654016-73-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(4,4,4-trifluorobutoxy)phenyl]- (CA INDEX NAME)



RN 654016-79-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(bicyclo[2.2.1]hept-5-en-2-ylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)




Updated Search

10501317

RN 654016-82-7 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-[(2-methyl-2-propen-1-yl)oxy]phenyl]- (CA INDEX NAME)



RN 654016-86-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-yloxy]phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 654016-90-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(2-butyln-1-yloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Updated Search




10501317



RN 654016-94-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(4,4,4-trifluoro-2-methylbutoxy)phenyl]- (CA INDEX NAME)




RN 654017-02-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-nitrophenoxy)phenyl]- (CA INDEX NAME)


Updated Search

10501317



RN 654017-07-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(2-(dimethylamino)ethoxy)phenyl]-1,3-dihydro-3-[4-(2-methylphenoxy)phenyl]- (CA INDEX NAME)




RN 654017-11-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(2-chlorophenoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)


Updated Search

10501317



RN 654017-15-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(2-(dimethylamino)ethoxy)phenyl]-1,3-dihydro-3-[4-(2-methoxyphenoxy)phenyl]- (CA INDEX NAME)




RN 654017-20-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(2-(dimethylamino)ethoxy)phenyl]-1,3-dihydro-3-[4-(3-methylphenoxy)phenyl]- (CA INDEX NAME)


Updated Search

10501317



RN 654017-25-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(3-chlorophenoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)




RN 654017-30-8 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(3-methoxyphenoxy)phenyl]- (CA INDEX NAME)


Updated Search

10501317



RN 654017-35-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(3-pyridinyloxy)phenyl]- (CA INDEX NAME)




RN 654017-40-0 HCAPLUS

CN 2H-Imidazol-2-one, 1-[1,1'-biphenyl]-4-yl-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)


Updated Search

10501317



RN 654017-45-5 HCAPLUS


CN 2H-Imidazol-2-one, 1-(4-butylphenyl)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)



RN 654017-50-2 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[2-methoxy-4-(phenylamino)phenyl]- (CA INDEX NAME)

10501317



RN 654017-55-7 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 654017-60-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(phenylmethyl)phenyl]- (CA INDEX NAME)


10501317



RN 654017-64-8 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(4-pyridinylmethoxy)phenyl]- (CA INDEX NAME)

PAGE 1-A








RN 654017-68-2 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(4-methylphenoxy)phenyl]- (CA INDEX NAME)



RN 654017-73-9 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(phenylthio)phenyl]- (CA INDEX NAME)

10501317



RN 654017-78-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-[3-(trifluoromethyl)phenoxy]phenyl]- (CA INDEX NAME)




RN 654017-83-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-(4-butyl-2-methylphenyl)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)


Updated Search

10501317



RN 654017-87-5 HCAPLUS


CN [1,1'-Biphenyl]-4-carbonitrile, 4'-[3-[4-[2-(dimethylamino)ethoxy]phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]- (CA INDEX NAME)



RN 654017-92-2 HCAPLUS


CN 2H-imidazol-2-one, 1-[3-chloro-4-(2-pyrimidinylloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

10501317



RN 654017-97-7 HCAPLUS


CN 3-Furancarboxylic acid, 5-[4-[3-[4-(2-(dimethylamino)ethoxy)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenyl]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 654018-02-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(1-piperidinylcarbonyl)phenyl]- (CA INDEX NAME)

10501317




RN 654018-07-2 HCAPLUS  
 CN 2H-imidazol-2-one, 1-[4-(2-(dimethylamino)ethoxy)phenyl]-3-[4-(1,1,2,2,3,3,3-heptafluoropropylthio)phenyl]-1,3-dihydro- (CA INDEX NAME)




RN 654018-12-9 HCAPLUS  
 CN 2H-imidazol-2-one, 1-[4-(2-(dimethylamino)ethoxy)phenyl]-3-[4-(4-fluorophenoxy)phenyl]-1,3-dihydro- (CA INDEX NAME)

Updated Search




RN 654018-17-4 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-pyrimidininyloxy)phenyl]- (CA INDEX NAME)




RN 654018-21-0 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(2-methoxy[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)

10501317




RN 654018-26-5 HCAPLUS  
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(6-methoxy[1,1'-biphenyl]-3-yl)- (CA INDEX NAME)



RN 654018-31-2 HCAPLUS  
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(1,3-dithiolan-2-yl)phenyl]-1,3-dihydro- (CA INDEX NAME)


Updated Search

10501317



RN 654018-36-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(2-(dimethylamino)ethoxy)phenyl]-1,3-dihydro-3-[4-(2-thienylthio)phenyl]- (CA INDEX NAME)




RN 654018-41-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[3-chloro-4-(1-piperidinyl)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Updated Search




10501317



RN 654018-46-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-{2-(dimethylamino)ethoxy}phenyl]-3-[4-(2-fluorophenoxy)phenyl]-1,3-dihydro- (CA INDEX NAME)




RN 654018-51-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-[4-{2-(dimethylamino)ethoxy}phenyl]-1,3-dihydro- (CA INDEX NAME)


Updated Search

10501317



RN 654018-56-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 654019-01-9 HCAPLUS

CN 2-Imidazolidinone, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)


Updated Search

10501317



RN 654019-07-5 HCAPLUS


CN 2-Imidazolidinone, 1-[4-(cyclopropylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 654019-28-0 HCAPLUS

CN Acetamide, N-[2-[4-[3-[4-(cyclopentyloxy)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenoxy]ethyl]-N-methyl- (CA INDEX NAME)


10501317



RN 654019-35-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4H-1,2,4-triazol-4-yl)ethoxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




10501317


PAGE 2-A



RN 654019-41-7 HCAPLUS  
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-  
[(cyclopropylmethyl)methylamino]ethoxy]phenyl]-1,3-dihydro- (CA INDEX  
NAME)


PAGE 1-A







RN 654019-47-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)

MeO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>2</sub>-O


RN 654019-52-0 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[(1-hydroxycyclohexyl)methyl]amino]ethoxy]phenyl]- (CA INDEX NAME)



RN 654019-57-5 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(4-acetyl-1-piperazinyl)ethoxy]phenyl]-3-[4-(cyclopentyloxy)phenyl]-1,3-dihydro- (CA INDEX NAME)


10501317




RN 654019-63-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-{2-(4-hydroxy-1-piperidinyl)ethoxy}phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A






10501317


RN 654019-69-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-methyl-1-piperidinyloxy)ethoxy]phenyl]- (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 654019-73-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(cyclopropylamino)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Updated Search




RN 654019-79-1 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-[2-(cyclohexylamino)ethoxy]phenyl]-3-[4-(cyclopentyloxy)phenyl]-1,3-dihydro- (CA INDEX NAME)




RN 654019-84-8 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[(1-methylethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)

10501317





RN 654019-89-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-{2-(4-ethyl-1-piperazinyl)ethoxy}phenyl]-1,3-dihydro- (CA INDEX NAME)




RN 654019-94-0 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-{2-(2,5-dimethyl-1-pyrrolidinyl)ethoxy}phenyl]-1,3-dihydro- (CA INDEX NAME)



RN 654019-99-5 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[methyl(1-methylethyl)amino]ethoxy]phenyl]- (CA INDEX NAME)


10501317



RN 654020-05-0 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 654020-10-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(7-azabicyclo[2.2.1]hept-7-yl)ethoxy]phenyl]-3-[4-(cyclopentyloxy)phenyl]-1,3-dihydro- (CA INDEX NAME)

Updated Search


10501317




RN 654020-15-2 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-[3-(dimethylamino)-1-pyrrolidinyl]ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

PAGE 1-A







RN 654020-20-9 HCAPLUS  
 CN Acetamide, N-[1-[2-[4-[3-[4-(cyclopentyloxy)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenoxy]ethyl]-3-pyrrolidinyl]- (CA INDEX NAME)









RN 654020-25-4 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-hydroxy-4-phenyl-1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)







RN 654020-29-8 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(3-hydroxy-1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)





RN 654020-35-6 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2-methyl-1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)






RN 654020-41-4 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-[4-[3-[4-(cyclopentyloxy)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenoxy]ethyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 654020-46-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[(2-methoxyethyl)methylamino]ethoxy]phenyl]- (CA INDEX NAME)


10501317




RN 654020-51-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-{2-(2-methyl-1H-imidazol-1-yl)ethoxy}phenyl]- (CA INDEX NAME)

PAGE 1-A





Updated Search



RN 654020-56-1 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-(2-(4-methyl-1H-imidazol-1-yl)ethoxy)phenyl]- (CA INDEX NAME)







RN 654020-60-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(2-ethyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)






RN 654020-66-3 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(2,4-dimethyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)









RN 654020-71-0 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(2-chloro-1H-imidazol-1-yl)ethoxy]phenyl]-3-[4-(cyclopentyloxy)phenyl]-1,3-dihydro- (CA INDEX NAME)






RN 654020-75-4 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(2-ethyl-4-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)






RN 654020-80-1 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[2-(1-methylethyl)-1H-imidazol-1-yl]ethoxy]phenyl]- (CA INDEX NAME)






RN 654020-86-7 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2,4,5-trimethyl-1H-imidazol-1-yl)ethoxy]phenyl]- (CA INDEX NAME)






RN 654020-92-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2-nitro-1H-imidazol-1-yl)ethoxy]phenyl]- (CA INDEX NAME)



10501317


PAGE 2-A




RN 654020-99-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-nitro-1H-imidazol-1-yl)ethoxy]phenyl]- (CA INDEX NAME)


PAGE 1-A




Updated Search




RN 654021-04-2 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2-methyl-4-nitro-1H-imidazol-1-yl)ethoxy]phenyl]- (CA INDEX NAME)






RN 654021-10-0 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(5-methyl-4-nitro-1H-imidazol-1-yl)ethoxy]phenyl]- (CA INDEX NAME)









RN 654021-16-6 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(4,5-dichloro-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)






RN 654021-22-4 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2-phenyl-1H-imidazol-1-yl)ethoxy]phenyl]- (CA INDEX NAME)







RN 654021-27-9 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-phenyl-1H-imidazol-1-yl)ethoxy]phenyl]- (CA INDEX NAME)







RN 654021-32-6 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)





RN 654021-37-1 HCAPLUS  
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(4,5-dihydro-4,4-dimethyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (CA INDEX NAME)





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:80660 HCAPLUS  
 DOCUMENT NUMBER: 140:146137  
 TITLE: Preparation of (phenylureido)benzoic acid compounds for use in suppression of nonsense mRNA mutations and the treatment of genetic disease  
 INVENTOR(S): Wilde, Richard G.; Takasugi, James J.; Hwang, Seongwoo; Welch, Ellen M.; Chen, Guangming  
 PATENT ASSIGNEE(S): PTC Therapeutics, Inc., USA  
 SOURCE: PCT Int. Appl., 134 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009558	A2	20040129	WO 2003-US23182	20030723
WO 2004009558	A3	20040415		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2493458	A1	20040129	CA 2003-2493458	20030723
AU 2003256755	A1	20040209	AU 2003-256755	20030723
EP 1542667	A2	20050622	EP 2003-766012	20030723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK US 20060167065 A1 20060727 US 2005-48656 20050121 US 7405233 B2 20080729				
PRIORITY APPLN. INFO.:			US 2002-398333P P 20020724	
			WO 2003-US23182 W 20030723	


10501317

OTHER SOURCE(S):  
GI

MARPAT 140:146137



I



II

AB Title compds., including (oxoimidazolidinyl)benzoic acid derivs., I [wherein R = H or (un)substituted (cyclo)alkyl, heterocyclyl, (hetero)aryl, (hetero)arylalkyl, cycloalkylalkyl, heterocycloalkyl; R1, R2 = independently H or (un)substituted alkyl, alkenyl, alkyloxyalkyl, amide, sulfonyl, or together form 5-7 membered (un)substituted heterocyclic ring or heteroaryl ring, etc.; R3-R6 = independently H, halogen, (un)substituted heterocyclo, heteroarylalkyl, haloalkoxy, etc.; X = CO, CS, S, SO, SO2; Y = (un)substituted (cyclo)alkyl, (hetero)aryl, heterocyclo; n = 1-4; and salts, hydrates, solvates, clathrate or stereoisomer thereof] were prepared as anticancer agents for treatment of genetic diseases (no data). For example, reaction of 3-aminobenzoic acid with 4-isopropylphenyl isocyanate gave II in 85% yield, which was formulated in the aerosol dosage form. Thus, I and their pharmaceutical compds. are useful for nonsense suppression and the treatment of genetic diseases as anticancer agents (no data).


IT 651749-02-9P 651749-18-7P 651749-19-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (phenylureido)benzoic acid compds. for use in suppression of nonsense mRNA mutations and the treatment of genetic disease)

RN 651749-02-9 HCAPLUS


CN Benzoic acid, 3-[2-oxo-3-[4-[2-oxo-2-(4-phenyl-1-piperazinyl)ethoxy]phenyl]-1-imidazolidinyl]- (CA INDEX NAME)

10501317




RN 651749-18-7 HCAPLUS

CN Benzoic acid, 3-[3-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-2-oxo-1-imidazolidinyl]- (CA INDEX NAME)



RN 651749-19-8 HCAPLUS

CN Benzoic acid, 3-[3-[4-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]phenyl]-2-oxo-1-imidazolidinyl]- (CA INDEX NAME)



=> file caold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

51.67	233.46
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-6.40	-6.40
-------	-------

FILE 'CAOLD' ENTERED AT 17:50:46 ON 10 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are

Updated Search



now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAOLD will be discontinued and removed from associated database clusters.

- . November 22, 2008 - removed from database clusters
- . December 31, 2008 - removed from STN

Content previously available only in CAOLD is now available in CA/Caplus. To learn more about the options available for transferring saved search queries and answer sets to CA/Caplus, contact your STN Service Center.

=> d his

(FILE 'HOME' ENTERED AT 17:44:07 ON 10 OCT 2008)

FILE 'REGISTRY' ENTERED AT 17:44:16 ON 10 OCT 2008

```
L1      STRUCTURE UPLOADED
L2      14 S L1
L3      247 S L1 FULL
```

FILE 'HCAPLUS' ENTERED AT 17:49:04 ON 10 OCT 2008

```
L4      8 S L3
L5      2 S L4 AND BROMIDGE, S?/AU
L6      6 S L4 NOT L5
L7      0 S L6 AND LOVELL, P?/AU
L8      0 S L6 AND GOODACRE, C?/AU
```

FILE 'CAOLD' ENTERED AT 17:50:46 ON 10 OCT 2008

=> s l3

```
L9      0 L3
```

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.46	233.92

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-6.40

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 17:50:57 ON 10 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

10501317

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 OCT 2008 HIGHEST RN 1059172-07-4  
DICTIONARY FILE UPDATES: 9 OCT 2008 HIGHEST RN 1059172-07-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\e-Red Folder\10524345\317a.str

L10 STRUCTURE UPLOADED

=> s l10

SAMPLE SEARCH INITIATED 17:52:49 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2434 TO ITERATE

82.2% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 45721 TO 51639  
PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L10

=> s l10 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 17:52:53 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 48879 TO ITERATE

100.0% PROCESSED 48879 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.02

L12 1 SEA SSS FUL L10

=> d his

(FILE 'HOME' ENTERED AT 17:44:07 ON 10 OCT 2008)

Updated Search

10501317

FILE 'REGISTRY' ENTERED AT 17:44:16 ON 10 OCT 2008  
L1 STRUCTURE UPLOADED  
L2 14 S L1  
L3 247 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:49:04 ON 10 OCT 2008  
L4 8 S L3  
L5 2 S L4 AND BROMIDGE, S7/AU  
L6 6 S L4 NOT L5  
L7 0 S L6 AND LOVELL, P7/AU  
L8 0 S L6 AND GOODACRE, C7/AU

FILE 'CAOLD' ENTERED AT 17:50:46 ON 10 OCT 2008  
L9 0 S L3

FILE 'REGISTRY' ENTERED AT 17:50:57 ON 10 OCT 2008  
L10 STRUCTURE UPLOADED  
L11 0 S L10  
L12 1 S L10 FULL

=> s l12 not l3  
L13 1 L12 NOT L3

=> file hcaplus		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		179.74	413.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		SINCE FILE	TOTAL
		ENTRY	SESSION
CA SUBSCRIBER PRICE		0.00	-6.40

FILE 'HCAPLUS' ENTERED AT 17:53:09 ON 10 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Oct 2008 VOL 149 ISS 16  
FILE LAST UPDATED: 9 Oct 2008 (20081009/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Updated Search

10501317

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l13

L14 2 L13

=> s l14 and bromidge, s?/au

82 BROMIDGE, S?/AU

L15 2 L14 AND BROMIDGE, S?/AU

=> d l15, ibib abs hitstr, 1-2

L15 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1084921 HCAPLUS

DOCUMENT NUMBER: 143:432011

TITLE: A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT<sub>2C</sub> receptor antagonists

AUTHOR(S): Goodacre, Caroline J.; Bromidge, Steven M.; Clapham, David; King, Frank D.; Lovell, Peter J.; Allen, Mike; Campbell, Lorraine P.; Holland, Vicky; Riley, Graham J.; Starr, Kathryn R.; Trail, Brenda K.; Wood, Martyn D.

CORPORATE SOURCE: Psychiatry Centre of Excellence in Drug Discovery, GlaxoSmithkline Pharmaceuticals, Essex, CM19 5AW, UK  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(22), 4989-4993

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:432011

GI



AB Bisaryl cyclic ureas have been identified as high affinity 5-HT<sub>2C</sub> receptor antagonists with selectivity over 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub>. Compds. such as (I) and (II) have shown oral activity in a centrally mediated pharmacodynamic model of 5-HT<sub>2C</sub> function in rodents.

IT 561277-48-3P

Updated Search

10501317


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT<sub>2C</sub> receptor antagonists)

RN 561277-48-3 HCAPLUS

CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:551382 HCAPLUS

DOCUMENT NUMBER: 139:117423

TITLE: Preparation of cyclic urea derivatives with 5-HT<sub>2C</sub> receptor activity

INVENTOR(S): Bromidge, Steven Mark; Lovell, Peter John;

Updated Search



10501317

PATENT ASSIGNEE(S): Goodacre, Caroline  
 SOURCE: Glaxo Group Limited, UK  
 PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057220	A1	20030717	WO 2003-GB20	20030107
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003201636	A1	20030724	AU 2003-201636	20030107
EP 1465630	A1	20041013	EP 2003-700335	20030107
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005524620	T	20050818	JP 2003-557578	20030107
US 20050154028	A1	20050714	US 2005-501317	20050222
PRIORITY APPLN. INFO.:			GB 2002-283	A 20020108
			WO 2003-GB20	W 20030107

OTHER SOURCE(S): MARPAT 139:117423

GI




AB Title compds. I [p = 0-5; m = 1-3; Y = N, C; A = O, N, CONH, NHCO, etc.;  
 R1 = halo, alkyl, alkoxy, alkylthio, etc.; R2 = H, halo, alkyl, alkoxy,

Updated Search

haloalkyl, haloalkoxy; R3 = amino; X = CH2, CO] are prepared For instance, 2-(3-fluorophenylamino)ethanol (preparation given) is reacted with MsCl/CH2Cl2 followed by 3-benzyloxy-4-methoxyphenylamine to give the corresponding substituted diamine. This intermediate is treated with phosgene to give 1-(3-benzyloxy-4-methoxyphenyl)-3-(3-fluorophenyl)imidazolidin-2-one. Substitution of this using 1-(2-chloroethyl)piperidine•HCl (MeOCH2CH2OMe, K2CO3, reflux, 5 h) afforded II. I exhibit 5-HT2c receptor activity and are useful for the treatment of CNS disorders such as depression or anxiety.

- IT 561277-48-3P, 1-(3,4-Dichlorophenyl)-3-[6-(2-(piperidinyl)ethoxy)pyridin-3-yl]imidazolidin-2-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of cyclic urea derivs. with 5-HT2C receptor activity)  
 RN 561277-48-3 HCAPLUS  
 CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



10501317

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	13.59	427.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.60	-8.00

FILE 'CAOLD' ENTERED AT 17:53:25 ON 10 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAOLD will be discontinued and removed from associated database clusters.

- . November 22, 2008 - removed from database clusters
- . December 31, 2008 - removed from STN

Content previously available only in CAOLD is now available in CA/Caplus. To learn more about the options available for transferring saved search queries and answer sets to CA/Caplus, contact your STN Service Center.

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.46	427.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

FILE 'HCAPLUS' ENTERED AT 17:53:31 ON 10 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

Updated Search



10501317

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Oct 2008 VOL 149 ISS 16  
FILE LAST UPDATED: 9 Oct 2008 (20081009/ED)

HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 17:44:07 ON 10 OCT 2008)

FILE 'REGISTRY' ENTERED AT 17:44:16 ON 10 OCT 2008

L1 STRUCTURE UPLOADED  
L2 14 S L1  
L3 247 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:49:04 ON 10 OCT 2008

L4 8 S L3  
L5 2 S L4 AND BROMIDGE, S?/AU  
L6 6 S L4 NOT L5  
L7 0 S L6 AND LOVELL, P?/AU  
L8 0 S L6 AND GOODACRE, C?/AU

FILE 'CAOLD' ENTERED AT 17:50:46 ON 10 OCT 2008

L9 0 S L3

FILE 'REGISTRY' ENTERED AT 17:50:57 ON 10 OCT 2008

L10 STRUCTURE UPLOADED  
L11 0 S L10  
L12 1 S L10 FULL  
L13 1 S L12 NOT L3

FILE 'HCAPLUS' ENTERED AT 17:53:09 ON 10 OCT 2008

L14 2 S L13  
L15 2 S L14 AND BROMIDGE, S?/AU

FILE 'CAOLD' ENTERED AT 17:53:25 ON 10 OCT 2008

Updated Search

10501317

FILE 'HCAPLUS' ENTERED AT 17:53:31 ON 10 OCT 2008

=> s l13/uses  
2 L13  
7232791 USES/RL  
L16 2 L13/USES  
(L13 (L) USES/RL)

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.69	430.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

FILE 'HCAPLUS' ENTERED AT 17:53:43 ON 10 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Oct 2008 VOL 149 ISS 16  
FILE LAST UPDATED: 9 Oct 2008 (20081009/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.69	433.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

FILE 'REGISTRY' ENTERED AT 17:53:47 ON 10 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Updated Search

10501317

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 OCT 2008 HIGHEST RN 1059172-07-4

DICTIONARY FILE UPDATES: 9 OCT 2008 HIGHEST RN 1059172-07-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 17:44:07 ON 10 OCT 2008)

FILE 'REGISTRY' ENTERED AT 17:44:16 ON 10 OCT 2008

L1 STRUCTURE UPLOADED

L2 14 S L1

L3 247 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:49:04 ON 10 OCT 2008

L4 8 S L3

L5 2 S L4 AND BROMIDGE, S?/AU

L6 6 S L4 NOT L5

L7 0 S L6 AND LOVELL, P?/AU

L8 0 S L6 AND GOODACRE, C?/AU

FILE 'CAOLD' ENTERED AT 17:50:46 ON 10 OCT 2008

L9 0 S L3

FILE 'REGISTRY' ENTERED AT 17:50:57 ON 10 OCT 2008

L10 STRUCTURE UPLOADED

L11 0 S L10

L12 1 S L10 FULL

L13 1 S L12 NOT L3

FILE 'HCAPLUS' ENTERED AT 17:53:09 ON 10 OCT 2008

L14 2 S L13

L15 2 S L14 AND BROMIDGE, S?/AU

FILE 'CAOLD' ENTERED AT 17:53:25 ON 10 OCT 2008

FILE 'HCAPLUS' ENTERED AT 17:53:31 ON 10 OCT 2008

L16 2 S L13/USES

Updated Search

10501317

FILE 'HCAPLUS' ENTERED AT 17:53:43 ON 10 OCT 2008

FILE 'REGISTRY' ENTERED AT 17:53:47 ON 10 OCT 2008

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\e-Red  
Folder\10524345\317\b.str

L17        STRUCTURE UPLOADED

=> s l17

SAMPLE SEARCH INITIATED 17:56:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        2434 TO ITERATE

82.2% PROCESSED        2000 ITERATIONS        0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        45721 TO        51639

PROJECTED ANSWERS:                0 TO                0

L18                0 SEA SSS SAM L17

=> s l17 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 17:56:19 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -        48879 TO ITERATE

100.0% PROCESSED        48879 ITERATIONS        0 ANSWERS  
SEARCH TIME: 00.00.02

L19                0 SEA SSS FUL L17

Updated Search